Lot-to-lot consistency: why the same peptide isn't the same

Two vials can carry the same name, the same nominal purity and the same certificate format — and still behave differently. The difference is usually not fraud. It is normal process variation that nobody trended.

Where variation comes from

Synthesis scale. A 1 g run and a 100 g run do not have identical coupling efficiency; impurities scale differently.
Purification. Gradient shape, column load and fraction cut points determine which impurities are removed and which survive.
Counter-ion exchange. The same peptide as acetate and as TFA differs in mass, solubility and pH in solution.
Lyophilization. Cycle changes affect residual moisture, cake structure and reconstitution behaviour.
Raw materials. Resin and amino acid suppliers change; a new lot of resin can shift the impurity profile.

What a purity number hides

“98% by HPLC” says the main peak is 98% of the integrated area at one wavelength. It does not tell you what the other 2% is, whether the method resolved related impurities, or whether the same impurity is present in every lot. A lot that is 98% pure with a growing deletion sequence is a different product from a lot that is 98% pure with a stable profile.

Four practical controls

Control	What it catches	Effort
Retention sample per lot	Enables side-by-side retest and visual comparison later	Low — ask for it in the contract
Full chromatogram, not just a number	Impurity profile changes that purity alone conceals	Low — require the PDF attachment
Trend table across lots	Slow drift in purity, water content or appearance	Medium — a simple spreadsheet
Periodic independent retest	Divergence between supplier COA and reality	Medium — cost per lot, sample the critical ones

Reading a trend, not a certificate

Ask for the last several lots of the same SKU and plot purity, water content and appearance against date. Stable numbers with a stable chromatogram shape are reassuring. A purity figure that sits at 98.1, 98.0, 97.9, 97.8 over a year is technically in spec but describes a process moving in one direction. The question to ask is what changed — column, resin, scale or operator.

Specifications that actually constrain drift

Purity by a named method, with a minimum and a defined integration threshold
Maximum unspecified impurity, not only total purity
Water content range by Karl Fischer
Counter-ion form and residual solvent limits where relevant
Appearance and reconstitution description
Lot-to-lot comparability statement: the supplier confirms the impurity profile is consistent with the prior lot

When a new lot is not interchangeable

If your work depends on a specific lot — an assay, a stability study, a reference standard — freeze enough of that lot to finish the work. Treating a new batch as a drop-in replacement is an assumption, not a control. Where interchangeability matters, ask for a comparability package before you switch.

Research use only. This article describes quality-control practice; it makes no claim about any specific compound.

Editor's take

Buyers ask for a COA. They should ask for three. One clean lot proves a batch; three comparable lots prove a process, and the process is what you are actually buying.

Sources & evidence

Method validation: ICH Q2(R1) — ICH quality guidelines.
Specifications: ICH Q6B — same ICH page.
Water / particulates / endotoxin: USP <731>, <788>, <85> — USP.
Chinese Pharmacopoeia (ChP 2020) Part IV: chapters 0512, 0832, 0903, 1143 — cited by chapter number.

No laboratory testing was performed by the author for this guide; acceptance limits must come from your own specification.

Limitations

This guide describes methods and interpretation, not acceptance limits. Limits must come from your own specification and, where applicable, the relevant pharmacopoeial monograph. No testing was performed by the author for this page.